Details Of Published TSH Receptor Mutation
Thr 632 Ile
c.1895C>TConstitutively Activating TSH Receptor Mutation
Type
gain
Manifestation
carcinoma
Exon
10
Molecular Characteristics:
default
Clinical Features:
follicular carcinoma with clinical phenotype of "hot nodule"
*based on 50 hot nodules investigated by Paschke et al. 1994, Parma et al. 1997, Duprez et al. 1997, Russo et al. 1996, Holzapfel et al. 1997, Porcellini et al. 1994, Tonacchera et al. 1998, Fuhrer et al. 1997, Tassi et al. 1999, Derwahl et al. 1996, Tonacchera et al. 1998 and 2000, Georgopoulos et al. 2003, Gozu et al. 2005 and 2006, Trulzsch et al. 2001, Palos-Paz et al. 2008, Sancak et al. 2011, Nishihara et al. 2009
and on 1 activating sporadic germline mutation investigated by Kopp et a. 1997
and on 2 hot thyroid carcinoma investigated by Spambalg et al. 1996 and
*based on 50 hot nodules investigated by Paschke et al. 1994, Parma et al. 1997, Duprez et al. 1997, Russo et al. 1996, Holzapfel et al. 1997, Porcellini et al. 1994, Tonacchera et al. 1998, Fuhrer et al. 1997, Tassi et al. 1999, Derwahl et al. 1996, Tonacchera et al. 1998 and 2000, Georgopoulos et al. 2003, Gozu et al. 2005 and 2006, Trulzsch et al. 2001, Palos-Paz et al. 2008, Sancak et al. 2011, Nishihara et al. 2009
and on 1 activating sporadic germline mutation investigated by Kopp et a. 1997
and on 2 hot thyroid carcinoma investigated by Spambalg et al. 1996 and
Treatment:
default
Functional Characteristics:
cAMP
(basal)
(basal)
cAMP
(TSH)
(TSH)
IP
(basal)
(basal)
IP
(TSH)
(TSH)
TSH-Binding
Cell Surface Expression
Prevalence
LRA
Ref
3.7-5.0
0.8-1.0
1.0-1.3
0.7-1.0
-
n.d.
2
1,3,4
Legend:
cAMP (basal): basal in vitro cAMP production of mutant over wild-type TSHR
cAMP (TSH): maximal in vitro cAMP production of mutant over wild-type TSHR
IP (basal): basal in vitro IP production of mutant over wild-type TSHR
IP (TSH): maximal in vitro IP production of mutant over wild-type TSHR
TSH-binding: maximal TSH-binding compared to the wild-type TSHR
Cell surface expression: cell surface expression of mutant compared to WT-TSHR
LRA: linear regression analysis (LRA) of constitutive activity as a function of TSHR expression determined by 125I-bTSH binding or FACS analysis compared to the wild-type TSHR
Prevalence: Prevalence of (somatic and germline) activating mutations*
Ref: Reference for functional characterization
Child: Found in children.
Reference 1:
Paschke et al.
J. Clin. Endocrinol. Metab. 79: 1785-1789
Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid
1994
Reference 2:
Spambalg et al.
J. Clin. Endocrinol. Metab. 81: 3898-3901
Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
1996
Reference 3:
Kosugi et al.
FEBS Lett 356: 291-294
Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by four mutations in the 6th transmembrane helix of the human thyrotropin receptor.
1994
Reference 4:
Lüblinghoff et al.
J Endocrinol Invest 33:228-233
Lack of consistent association of thyrotropin receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism.
2010
Reference 5:
Eszlinger, Markus, et al.
Molecular and cellular endocrinology
Somatic mutations in 33 benign and malignant hot thyroid nodules in children and adolescents
2014